NEW YORK, April 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Pacira Pharmaceuticals Inc. Analyst Notes
On April 7, 2014, Pacira Pharmaceuticals, Inc. (Pacira) announced that it has entered into a strategic partnership with Patheon in manufacturing and packaging of EXPAREL at Patheon's facility in Swindon, UK. Under the terms of the agreement, Patheon will be responsible for the construction of the dedicated manufacturing suites, while Pacira will oversee the design and purchase of the dedicated EXPAREL manufacturing equipment to be installed in the Patheon facility. "Patheon has a long history of excellence in manufacturing sterile injection products," said Dave Stack, President, CEO and Chairman of Pacira. "With EXPAREL on a growth trajectory, we are confident that Patheon will ensure our ability to continue supplying EXPAREL to the marketplace beyond the capacity of our current Science Center manufacturing facility in San Diego." The full analyst notes on Pacira Pharmaceuticals Inc. are available to download free of charge at:
Celldex Therapeutics, Inc. Analyst Notes
On April 7, 2014, Celldex Therapeutics, Inc. (Celldex) announced results from preclinical studies evaluating the anti-tumor activity of CDX-014 - an antibody drug conjugate (ADC) that targets the protein TIM-1 - against a variety of cell lines. CDX-014 will enter clinical development based on the results. "We believe CDX-014 will be another exciting addition to our clinical pipeline," said Tibor Keler, PhD, Senior Vice President and Chief Scientific Officer of Celldex. "The data presented today confirm that CDX-014 effectively targets the tumor marker TIM-1 in vitro and elicits significant anti-tumor activity in key models. We are currently completing manufacturing and IND-enabling studies and anticipate that CDX-014 will enter Phase 1 clinical studies in renal cell carcinoma and potentially other TIM-1 expressing tumors in 2015." The full analyst notes on Celldex Therapeutics, Inc. are available to download free of charge at:
Aegerion Pharmaceuticals, Inc. Analyst Notes
On April 9, 2014, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that its patient enrollment has begun in Japan in a clinical trial of lomitapide as an adjunct treatment to reduce low-density lipoprotein cholesterol in Japanese patients with homozygous familial hypercholesterolemia (HoFH). "This pivotal trial marks an important milestone for Aegerion and Japanese HoFH patients," said Mark Sumeray, MD, Chief Medical Officer. "Japan is a well-characterized region for patients with severe hypercholesterolemia and investigators there have shown a high level of enthusiasm for the trial, recognizing the unmet clinical need for their patients living with this serious disease." HoFH is a serious, rare genetic disease inherited from both parents that impairs the function of the receptor responsible for removing LDL-C ("bad" cholesterol) from the body. HoFH patients often develop premature and progressive atherosclerosis, a narrowing or blocking of the arteries. The full analyst notes on Aegerion Pharmaceuticals, Inc. are available to download free of charge at:
Furiex Pharmaceuticals, Inc. Analyst Notes
On April 7, 2014, Furiex Pharmaceuticals, Inc. (Furiex) announced that it will release its Q1 2014 financial results on May 7, 2014, Wednesday. Furiex's earnings release will be available on the Company's website. In conjunction with the earnings release, the Company will hold a conference call on May 8, 2014, Thursday at 9:00 a.m. ET to discuss financial results and product portfolio. The full analyst notes on Furiex Pharmaceuticals, Inc. are available to download free of charge at:
Prothena Corporation plc Analyst Notes
On April 8, 2014, Prothena Corp plc (Prothena) announced that it has successfully completed initiation of a Phase 1 clinical trial of its therapeutic monoclonal antibody candidate, PRX002, for the treatment of Parkinson's disease. Prothena has earned a $15 million milestone payment from Roche related to the initiation of this study. "Together with Roche, we look forward to advancing this potential disease-modifying treatment for Parkinson's disease and other related synucleinopathies through clinical development," said Dale Schenk, PhD, President and CEO of Prothena. Prothena has now achieved a total of $45 million through its worldwide PRX002 collaboration with Roche. The full analyst notes on Prothena Corporation plc are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review